肺高血压的新诊断标准和当前问题
Kei Kusaka1, Keita Takeda1, Masahiro Kawashima1
1Department of Respiratory Medicine, NHO Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo, 204-8585, Japan; Center for Pulmonary Circulation and Hemoptysis, Department of Respiratory Medicine, NHO Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo, 204-8585, Japan.
新的2022年欧洲指南降低了肺高血压 (PH) 的诊断门,包括平均肺动脉压 (mPAP) 和肺血管阻力 (PVR). 这些变化可能会影响PH的诊断和管理.
科学领域:
- 心脏病学 心脏病学
- 呼吸系统医学 呼吸系统医学
- 肺高血压研究 肺高血压研究
背景情况:
- 肺高血压 (PH) 诊断依赖于特定的血液动力学标准.
- 之前的欧洲心脏病学会 (ESC) 和欧洲呼吸学会 (ERS) 的指导方针确立了诊断值.
- 不断发展的理解需要定期审查和对诊断标准的潜在更新.
研究的目的:
- 概述2022年ESC/ERS肺高血压诊断标准的修订.
- 详细说明血液动力学指数值的具体变化.
- 突出这些更新的标准对临床实践的影响.
主要方法:
- 对2022年ESC/ERS肺高血压诊断指南的审查和分析.
- 将新的血液动力学值 (mPAP,PVR) 与以前的标准进行比较.
- 包括重新引入的运动诱导PH的诊断标准.
- 检查拟议的差异值,以对肺部疾病中的PH严重程度进行分类.
主要成果:
- 肺动脉平均压力 (mPAP) 的下降值从≥25 mmHg降至≥20 mmHg.
- 肺血管阻力 (PVR) 的调整值从≥3木材单位 (WU) 到>2WU.
- 重新引入运动引起的PH作为诊断标准.
- 建议设置5 WU PVR值,以区分肺部疾病中的非严重和严重PH.
结论:
- 2022年ESC/ERS指南对PH诊断标准进行了重大修改.
- 降低血液动力学值可能导致更早或更广泛的PH识别.
- 这些变化需要仔细考虑诊断和管理的临床影响.
更多相关视频
相关概念视频
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...


